 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CALGARY, Alberta, Sept. 28, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company ) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology   Kidney Week 2023

In Support of Research for Treating the 4 Million Canadians Who Have Chronic Kidney Disease Today CALGARY, Alberta, Sept. 07, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the...

XORTX Joins the Kidney Foundation and Kidney March

XORTXs Proprietary Formulation of Oxypurinol XORLO to Treat Progressive Kidney Disease Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD) CALGARY, Alberta, Aug. 29, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (XORTXor the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), ...

XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease

XORTX Therapeutics names Fairbairn CFO

CALGARY, Alberta, Aug. 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the ...

XORTX Appoints Chief Financial Officer

The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023. XORTXs board of directors recommends shareholders vote FOR the election of all director nominees,FOR the appointment of auditors of the ensuing year, and FOR the resolution ...

XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company's Upcoming Annual and Special Meeting of Shareholders

CALGARY, Alberta, May 24, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that on May 23, ...

XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Expands Options for Accelerated ApprovalCALGARY, Alberta, May 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (XORTX or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...

XORTX Expands Options for Accelerated...

CALGARY, Alberta, April 21, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the ...

XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease

Type D Meeting Requested to Accelerate XRx-008 Clinical Program CALGARY, Alberta, March 14, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies ...

XORTX Announces Type D Meeting with FDA to be held May 1, 2023

XORTX Therapeutics, Inc. is a biopharmaceutical company. The firm engages in development and commercialization of innovative therapies. It focuses on drug therapies for rare orphan disease indications such as polycystic kidney disease, and the treatment of health consequences caused by chronic high serum uric acid or hyperuricemia, including Type 2 Diabetic Nephropathy, cardiovascular disease, and diabetes. The company was founded by Allen Davidoff on May 31, 2011 and is headquartered in Calgary, Canada.

Watchers	1,237
52-Wk Low	$0.41
52-Wk High	$1.28

Market Cap	$10.79M
Volume (M)	5,853.00
52-Wk High	$1.28
52-Wk Low	$0.41

XRTX XORTX Therapeutics Inc

About

Feed

News

Fundamentals